2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, (CAR)-T Cell Therapies, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Adverse Events, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Research, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1521 Predictors of central nervous system (CNS) relapse in adults with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia

Dany Nassar, MD, Hannah Goulart, MD2, Nicholas Short, MD3, Nitin Jain, MD4, Fadi G. Haddad, MD5, Jayastu Senapati, MBBS, MD, DM6, Eitan Kugler, MD PhD7, Rebecca Garris8, Guillermo Garcia-Manero, MD9, Hagop Kantarjian, MD10, Elias Jabbour, MD11
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Background:
Frontline treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has increasingly shifted from intensive chemotherapy toward reduced-intensity, chemotherapy-free regimens containing blinatumomab (blina) with potent tyrosine kinase inhibitors (TKIs). However, reducing systemic chemotherapy agents with central nervous system (CNS) activity has raised concern regarding CNS relapse. We evaluated the frequency, clinical characteristics, and predictors of CNS relapse in adults with Ph+ ALL.

Methods:
We retrospectively analyzed adults with newly diagnosed Ph+ ALL treated at our institution from 2001-2024. Frontline therapy was classified as intensive chemotherapy or lower-intensity blina-based therapy, including reduced-intensity chemotherapy plus blina and predominantly chemotherapy-free blina/TKI regimens. CNS relapse was characterized as either isolated CNS or combined CNS/systemic relapse. Relapse patterns, TKI use, and prophylactic IT chemotherapy administration were compared among relapsed patients. Multivariable fine-gray competing risks regression was performed to identify predictors of CNS relapse.

Results:
267 frontline patients analyzed had Ph+ ALL, of which 68 (26%) experienced any form of relapse. CNS relapse status was evaluable in 64 of the relapsed patients, of whom 22 (34%) had CNS involvement, leading to an overall rate of CNS relapse of 8% (22/267), with the remaining 42 patients (66%) demonstrating non-CNS involved relapse. Thirteen of the 22 CNS-involved relapses (59%) were isolated to the CNS without concurrent systemic (including measurable residual disease) involvement. The median interval from first complete remission to CNS relapse was 18.4 months (range, 6.6–92.7).

Baseline characteristics were similar between those with CNS-involved and non-CNS relapse: median age (48 years [22–70] vs 49 years [18–85]; p=.70), baseline WBC count (39 × 10⁹/L [0.6–658] vs 37 × 10⁹/L [0.9–538]; p=.90), median IT treatments (8 vs 8; p=.685), achievement of complete molecular response (CMR) 16/22 (72.7%) vs 23/42 (54.8%) (p = 0.188) There was also no significant difference in the IKZF1 status (p=.54), or baseline CNS involvement (p=.6). When comparing CNS-involved relapse to patients who did not relapse, age (p=.2), baseline WBC (p=NS), #IT chemo (p=.16), IKZF1 status (p=NS), baseline CNS involvement (p=.4), CMR status (p=.4) did not differ.

Among patients with CNS relapse, 18/22 (81%) were treated with intensive chemo and 4 (18%) with lower-intensity blina-based regimens (p=.793). Among patients who experienced any CNS relapse, isolated CNS relapse accounted for 9/18 events (50%) after intensive chemo and all 4 events (100%) after lower-intensity therapy; p=.115. Although CNS relapse rates did not differ significantly by frontline TKI, (p=.491), CNS relapse was numerically less frequent with ponatinib (6/22 [27.3%]) than with dasatinib (10/23 [43.5%]) or imatinib (6/15 [40.0%]).

Patients who experienced CNS involved relapse had a median OS of 17 months from the time of relapse. Post-relapse OS did not differ between patients with isolated CNS relapse and those with systemic relapse (HR, 1.12; 95% CI, 0.50–2.51; p=.776), with a median OS of 13 versus 17 months.

In multivariable Fine–Gray competing-risks regression to assess the risk of CNS relapse, with adjustment for age, presenting WBC >50 ×10⁹/L, number of IT treatments, treatment intensity, CMR attainment, and baseline CNS involvement, younger age (HR 0.74 per 10-year increase, 95% CI 0.57–0.96; p=.025) and baseline WBC >50 ×10⁹/L (HR 2.77, 95% CI 1.04–7.36; p=.042) were independently associated with increased risk of CNS relapse. The number of IT treatments (HR 0.86 per additional treatment, 95% CI 0.70–1.07; p=.19), CMR attainment (HR 1.26, 95% CI 0.41–3.85; p=.69), and baseline CNS involvement (HR 1.87, 95% CI 0.52–6.77; p=.34) were not independently associated with CNS relapse. Low-intensity therapy demonstrated a nonsignificant trend toward higher CNS relapse risk (HR 3.54, 95% CI 0.80–15.67; p=.096).

Conclusion:
CNS relapse occurred in 8% of patients with Ph+ ALL after a median of 18 months and represented approximately one-third of all relapses. Younger age and baseline WBC >50 × 10⁹/L independently identified patients at higher risk of CNS relapse, while achievement of CMR and #IT administered chemo were not. Further efforts are ongoing to optimize risk-adapted strategies to minimize the risk of CNS relapse in Ph+ ALL.

Dany Nassar, MD: No relevant conflicts of interest to declare.